CASI Pharmaceuticals (CASIF) Operating Income (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported Operating Income of -$77.2 million for Q4 2025, down 497.75% on a YoY basis from $19.4 million in Q4 2024, and down 622.98% quarter-over-quarter from -$10.7 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Operating Income (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Operating Income for 4 years, with the latest figure at -$77.2 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income fell 497.75% year-over-year to -$77.2 million; the trailing twelve-month figure through Dec 2025 stood at -$109.4 million (down 176.05% YoY), and the FY2025 full-year result was -$45.0 million, down 13.59% from the prior year.
- Operating Income for Q4 2025 stood at -$77.2 million, down from -$10.7 million in the prior quarter.
- The five-year high for Operating Income was $16.1 million in Q4 2023, with the low at -$77.2 million in Q4 2025.
- Historically, Operating Income has averaged -$11.8 million across 4 years, with a median of -$9.1 million in 2023.
- Annual changes were most pronounced in 2023 — Operating Income soared 207.78% — and 2025, when it plunged 497.75%.
- CASI Pharmaceuticals' Operating Income stood at -$15.0 million in 2022, then soared by 207.78% to $16.1 million in 2023, then plunged by 180.05% to -$12.9 million in 2024, then sank by 497.75% to -$77.2 million in 2025.
- The last three Operating Income figures came in at -$77.2 million (Q4 2025), -$10.7 million (Q3 2025), and -$11.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -65.83 Mn |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -77.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.19 Mn |
| Sep 30, 2025 | -10.68 Mn |
| Jun 30, 2025 | -11.13 Mn |
| Mar 31, 2025 | -10.38 Mn |
| Dec 31, 2024 | -12.91 Mn |
| Sep 30, 2024 | -8.46 Mn |
| Jun 30, 2024 | -8.79 Mn |
| Mar 31, 2024 | -9.45 Mn |
| Dec 31, 2023 | 16.13 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -9.35 Mn |
| Mar 31, 2023 | -7.21 Mn |
| Dec 31, 2022 | -14.97 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.96 Mn |